We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
LAGEVRIO molnupiravir 200 mg capsules bottle, Merck Sharp Dohme Pty Ltd, CON-909
Product name
LAGEVRIO molnupiravir 200 mg capsules bottle
Sponsor name
Merck Sharp Dohme Pty Ltd
Consent start
Consent no.
CON-909
Duration
The consent is effective for all batches released for supply from 18 January 2022 until 18 January 2024.
Standard
Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines (TGO 91)
Non-compliance with standard
The product does not conform to the requirements of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines (TGO 91).
Conditions imposed
The product must be supplied with the labels that were considered and agreed to as part of the evaluation under section 25 of the Therapeutic Goods Act 1989, being
a. The international label as follows
i. Carton labels (submitted 16 November 2021)
ii. Bottle labels (submitted 16 November 2021)
Import, Supply, &/or Export
Import and supply
Therapeutic product type
Prescription medicines